EUVIMEDEUVIMED entdecken
Systematische ÜbersichtNetzwerk-MetaanalyseOpen Access

Optimal Antithrombotic Therapy for Peripheral Artery Disease: A Systematic Review and Network Meta‐Analysis

Yuriko Hiruma iD, Atsuyuki Watanabe iD, Tadao Aikawa iD, Masao Iwagami iD, Leandro Slipczuk iD, Jose Wiley iD, Alexandros Briasoulis iD, Eric Secemsky iD, Roger Laham iD, Toshiki Kuno iD

Journal of the American Heart Association · 2026

DOI: 10.1161/jaha.125.047301 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Journal of the American Heart Association, 2026. Verfasst von Yuriko Hiruma und 9 weiteren Autor:innen. Beteiligte Einrichtung: United States Naval Hospital Okinawa Okinawa Japan. Hauptthemen laut MEDLINE: Peripheral Arterial Disease, Fibrinolytic Agents, Platelet Aggregation Inhibitors. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The optimal antithrombotic regimen for peripheral artery disease, balancing thromboembolic and bleeding risks, remains uncertain. This study aimed to compare the efficacy and safety of antithrombotic regimens in patients with peripheral artery disease.

Methods

We reviewed randomized controlled trials evaluating antithrombotic therapies for peripheral artery disease, including aspirin, P2Y12 inhibitors, cilostazol, and rivaroxaban. The primary outcome was major adverse cardiac events, defined as a composite of cardiovascular death, myocardial infarction, and stroke. The secondary outcomes included major adverse limb events, defined as a composite of acute limb ischemia, revascularization, and amputation. The safety outcome was major bleeding, primarily assessed using the Thrombolysis in Myocardial Infarction criteria. We performed a network meta‐analysis to compare antithrombotic regimens.

Results

Seventeen randomized controlled trials involving 44 532 participants were included. Compared with aspirin monotherapy, the following were associated with lower risks of major adverse cardiac events: clopidogrel, 75 mg/d, plus cilostazol, 200 mg/d (hazard ratio [HR], 0.37 [95% CI, 0.20–0.72]), clopidogrel, 75 mg/d, monotherapy (HR, 0.80 [95% CI, 0.67–0.96]), aspirin plus low‐dose rivaroxaban, 2.5 mg twice daily (HR, 0.81 [95% CI, 0.72–0.92]), and aspirin plus ticagrelor, 60 to 90 mg twice daily (HR, 0.81 [95% CI, 0.69–0.96]). Aspirin plus rivaroxaban or ticagrelor showed a lower risk of major adverse limb events compared with aspirin alone. Rivaroxaban monotherapy, 5 mg twice daily, and aspirin plus rivaroxaban or clopidogrel were associated with a higher risk of major bleeding.

Conclusions

Clopidogrel plus cilostazol or clopidogrel monotherapy might be a balanced strategy in patients with peripheral artery disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Peripheral Arterial DiseaseFibrinolytic AgentsPlatelet Aggregation InhibitorsHumansHemorrhageRandomized Controlled Trials as TopicTreatment OutcomeCilostazolDrug Therapy, CombinationRisk Factors

Stichwörter der Autor:innen

anticoagulationantiplateletantithrombotic therapycardiovascular diseaseperipheral artery disease

Substanzen

Fibrinolytic AgentsPlatelet Aggregation InhibitorsCilostazol

Autor:innen und Institutionen

  • United States Naval Hospital Okinawa Okinawa Japan.
  • Mount Sinai Morningside and West Icahn School of Medicine at Mount Sinai New York NY.
  • Department of Cardiovascular Biology and Medicine Juntendo University Graduate School of Medicine Tokyo Japan.
  • Department of Non-Communicable Disease Epidemiology, Faculty of Epidemiology and Population Health London School of Hygiene and Tropical Medicine London UK.
  • Department of Digital Health, Institute of Medicine University of Tsukuba Tsukuba Japan.
  • Division of Cardiology Montefiore Health System/Albert Einstein College of Medicine Bronx NY.

ORCID-Profile: Yuriko Hiruma, Atsuyuki Watanabe, Tadao Aikawa, Masao Iwagami, Leandro Slipczuk, Jose Wiley, Alexandros Briasoulis, Eric Secemsky, Roger Laham, Toshiki Kuno

Zitieren

APA

Hiruma, Y., Watanabe, A., Aikawa, T., Iwagami, M., Slipczuk, L., Wiley, J., Briasoulis, A., Secemsky, E., Laham, R., & Kuno, T. (2026). Optimal Antithrombotic Therapy for Peripheral Artery Disease: A Systematic Review and Network Meta‐Analysis. Journal of the American Heart Association. https://doi.org/10.1161/jaha.125.047301

Vancouver

Hiruma Y, Watanabe A, Aikawa T, Iwagami M, Slipczuk L, Wiley J, et al. Optimal Antithrombotic Therapy for Peripheral Artery Disease: A Systematic Review and Network Meta‐Analysis. Journal of the American Heart Association. 2026. doi:10.1161/jaha.125.047301

BibTeX
@article{Hiruma2026,
  author = {Hiruma, Yuriko and Watanabe, Atsuyuki and Aikawa, Tadao and Iwagami, Masao and Slipczuk, Leandro and Wiley, Jose and Briasoulis, Alexandros and Secemsky, Eric and Laham, Roger and Kuno, Toshiki},
  title = {Optimal Antithrombotic Therapy for Peripheral Artery Disease: A Systematic Review and Network Meta‐Analysis},
  journal = {Journal of the American Heart Association},
  year = {2026},
  doi = {10.1161/jaha.125.047301}
}
Kostenlos starten →